Vertex Pharmaceuticals price target lowered to $520 from $566

Dec 20, 2024 · BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares. The company’s Suzetrigine …

$520
OFF

Vertex Pharmaceuticals Price Target Lowered To $520 From $566

4 weeks from now

Dec 20, 2024 · BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares. The company’s Suzetrigine …

nasdaq.com

$566.00
OFF

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives …

4 weeks from now

9 hours ago · BMO Capital Markets lowered their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating for the company in a research note on …

marketbeat.com

$566.00
OFF

BMO Capital Markets Has Lowered Expectations For Vertex …

4 weeks from now

Dec 20, 2024 · BMO Capital Markets lowered their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a …

marketbeat.com

$566.00
OFF

BMO Capital Markets Cuts Vertex Pharmaceuticals …

4 weeks from now

Dec 23, 2024 · Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective lowered by BMO Capital Markets from $566.00 to $520.00 in a research report report …

americanbankingnews.com

$520
OFF

Vertex Pharmaceuticals Incorporated: Target Price Consensus And ...

4 weeks from now

5 days ago · BMO Capital Cuts Price Target on Vertex Pharmaceuticals to $520 From $566 Dec. 19: MT Stifel Adjusts Price Target on Vertex Pharmaceuticals to $494 From $490, Maintains …

marketscreener.com

$520
OFF

Cautious Outlook On Vertex Pharmaceuticals Due To Suzetrigine’s ...

4 weeks from now

Dec 20, 2024 · Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital; Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein; Vertex could be …

businessinsider.com

$520
OFF

BMO Capital Cuts Price Target On Vertex Pharmaceuticals To $520 …

4 weeks from now

Dec 19, 2024 · -- Vertex Pharmaceuticals has an average rating of overweight and mean price target of $525.79, according to analysts polled by FactSet. Price: 391.19, Change: -56.31, …

marketscreener.com

$504.50
OFF

What Is The Current Price Target And Forecast For Vertex ...

4 weeks from now

6 days ago · Based on short-term price targets offered by 28 analysts, the average price target for Vertex Pharmaceuticals comes to $504.50. The forecasts range from a low of $325.00 to a …

zacks.com

$566.00
OFF

BMO Capital Markets Issues Pessimistic Forecast For Vertex ...

4 weeks from now

Dec 23, 2024 · Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target lowered by BMO Capital Markets from $566.00 to $520.00 in a research note released on …

etfdailynews.com

$520
OFF

Cautious Optimism For Vertex Pharmaceuticals: Suzetrigene’s …

4 weeks from now

Dec 20, 2024 · Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein Vertex could be …

businessinsider.com

$494.04
OFF

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

4 weeks from now

According to the 31 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $494.04. ... The even lighter blue range in the background of the two lines …

marketbeat.com

$520
OFF

Barclays Keeps Their Hold Rating On Vertex Pharmaceuticals (VRTX)

4 weeks from now

Dec 20, 2024 · Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein Vertex could be …

businessinsider.com

$566.00
OFF

BMO Capital Markets Has Lowered Expectations For Vertex …

4 weeks from now

Dec 22, 2024 · Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target cut by investment analysts at BMO Capital Markets from $566.00 to $520.00 in a report …

defenseworld.net

$566.00
OFF

JPMorgan Chase & Co. Lowers Vertex Pharmaceuticals …

4 weeks from now

Dec 25, 2024 · Finally, BMO Capital Markets lowered their target price on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research note on …

etfdailynews.com

$460
OFF

Vertex Pharmaceuticals Price Target Lowered To $460 From $550 At …

4 weeks from now

Dec 23, 2024 · Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy rating on the shares. The firm moderates its view …

yahoo.com

$500
OFF

Vertex Pharmaceuticals Price Target Lowered To $500 From $503 At ...

4 weeks from now

Dec 23, 2024 · JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares. Alyftrek’s approval with a …

nasdaq.com

$480.00
OFF

SK Wealth Management LLC Takes Position In Vertex …

4 weeks from now

1 day ago · Cantor Fitzgerald reissued an "overweight" rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Bank of …

marketbeat.com

46%
OFF

Should You Buy Vertex Pharmaceuticals On The Dip Before …

4 weeks from now

Dec 22, 2024 · Current Price. $408.76. Price as of December 27, 2024, 4:00 p.m. ET ... Vertex Pharmaceuticals (VRTX-0.46%) was on track to become one of this year's biotech winners, …

fool.com

$500.00
OFF

Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $500.00 Price …

4 weeks from now

Dec 23, 2024 · JPMorgan Chase & Co. lowered their target price on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a …

marketbeat.com

$430.00
OFF

Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price …

4 weeks from now

Dec 23, 2024 · BMO Capital Markets decreased their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating for the company in a …

marketbeat.com

FAQs about Vertex Pharmaceuticals price target lowered to $520 from $566 Coupon?

Is Vertex Pharmaceuticals (VRTX) a good stock to buy?

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target lowered by BMO Capital Markets from $566.00 to $520.00 in a research note released on Friday, Benzinga reports. The firm currently has an outperform rating on the pharmaceutical company’s stock. Several other equities analysts also recently commented on the company. ...

Is Vertex Pharmaceuticals a good buy?

Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $511.54, which is a 29.27% upside from current levels. In a report released today, Bernstein also reiterated a Hold rating on the stock with a $441.00 price target. ...

What is Morgan Stanley's Price target for Vertex Pharmaceuticals?

Morgan Stanley raised their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. ...

What is the average price target for Vertex Pharmaceuticals?

Based on short-term price targets offered by 28 analysts, the average price target for Vertex Pharmaceuticals comes to $501.18. The forecasts range from a low of $325.00 to a high of $602.00. The average price target represents an increase of 22.05% from the last closing price of $410.65. ...

How do I receive news & ratings for Vertex Pharmaceuticals?

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter. ...

What is the consensus rating for Vertex Pharmaceuticals?

The consensus rating score for Vertex Pharmaceuticals is 2.52 while the average consensus rating score for "medical" companies is 2.81. Learn more on how VRTX compares to other companies. Porter Stansberry’s latest video is going viral… ...